Rabies Postexposure Prophylaxis in Routine Practice in View of the New Centers for Disease Control and Prevention and World Health Organization Recommendations-Reference-Cited by-同舟云学术

Rabies Postexposure Prophylaxis in Routine Practice in View of the New Centers for Disease Control and Prevention and World Health Organization Recommendations

Published:2012-05-01 Issue:2 Volume:55 Page:201-205
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:Clinical Infectious Diseases

Author:

Uwanyiligira M.,Landry P.,Genton B.,de Valliere S.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/55/2/201/1057346/cis384.pdf

Reference12 articles.

1. Rabies vaccines: WHO position paper—Recommendations

2. Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals

3. Walking the dog and moving the cat: Rabies serology in the context of international pet travel schemes

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity and Safety of a Purified Vero Rabies Vaccine—Serum Free, Compared With 2 Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen in Healthy Adults in France: A Randomized, Controlled, Phase 3 Trial;Clinical Infectious Diseases;2024-03-13

2. Real-world evidence of rabies post-exposure prophylaxis in Serbia: Nation-wide observational study (2017–2019);Travel Medicine and Infectious Disease;2024-03

3. Safety and immunogenicity of a serum-free purified Vero rabies vaccine in comparison with the rabies human diploid cell vaccine (HDCV; Imovax® Rabies) administered in a simulated rabies post-exposure regimen in healthy adults;Vaccine;2023-12

4. Safety and immunogenicity of three dose levels of an investigational, highly purified Vero cell rabies vaccine: A randomized, controlled, observer-blinded, Phase II study with a simulated post-exposure regimen in healthy adults;Human Vaccines & Immunotherapeutics;2023-11-03

5. Safety and efficacy results of simulated post-exposure prophylaxis with human immune globulin (HRIG; KEDRAB) co-administered with active vaccine in healthy subjects: a comparative phase 2/3 trial;Human Vaccines & Immunotherapeutics;2019-09-24